| セッション情報 |
Hepatitis C i)Hepatitis C and HCC(I)
|
| タイトル |
IF4c-3 Hepatitis C Treatment in the Era of Direct-acting Antivirals
|
| 演者 |
Gregory Dore（Viral Hepatitis Clinical Research ProgramThe Kirby Institute/The University of New South Wales/St Vincent's HospitalAustralia） |
| 共同演者 |
|
| 抄録 |
The landscape of hepatitis C virus（HCV）therapy wil change considerably over the next decade with theprobable licensure of many HCV direct－acting antiviral（DAA）therapy agents． Phase皿trials evaluatingthe addition of HCV protease inhibitors telaprevir or boceprevir to pegylated interferon and ribavirin inboth HCV treatment naive and experienced populations with chronic H：CV genotype l have de血on－strated considerable improvements in sustained virological responsewith many patients able to shortentotal treatment duration from 48 weeks to 2436 weeks． Although these initial DAA－based treatment re－sults are encouragingadditional toxicityproblematic dosing schedulesand potential drug 一 drug interac－tions pose challenges for clinical management． Subsequent DAA agent＄including next generation pro－tease inhibitorsnucleos（t）ide analogues and NSsA inhibitors have improved tolerability and dosing sched－ules． Furtherunlike the initial protease inhibitorsmany of these DAA agents have cross－genotype activ－ity． Preliminary findings also indicate that interferon－free combination D AA regimens should cure HCVinfection in a high proportion of patientsfollowing 12 week nucleotide analogue and ribavirin （genotype 2／3） or 24 week protease inhibitor and NSsA inhibitor （genotype l b） therapy． The future for treatment ofHCV infection appears extremely encouragingwith the realistic prospect of well tolera／tedshort durationregimens that are curative in the vast majority of patients． |
| 索引用語 |
|
